IQVIA (NYSE:IQV) Upgraded to Buy at StockNews.com

IQVIA (NYSE:IQV) was upgraded by stock analysts at StockNews.com from a “hold” rating to a “buy” rating in a research report issued on Tuesday.

IQV has been the subject of a number of other research reports. Leerink Partners reissued an “outperform” rating and set a $248.00 target price (down previously from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. Barclays dropped their target price on shares of IQVIA from $255.00 to $235.00 and set an “overweight” rating for the company in a research report on Monday, February 3rd. Bank of America dropped their target price on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating for the company in a research report on Friday, December 13th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $270.00 price objective on shares of IQVIA in a research report on Monday, February 10th. Finally, Stephens started coverage on shares of IQVIA in a research report on Friday, December 20th. They issued an “overweight” rating and a $250.00 price objective for the company. Four analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $249.05.

IQVIA Trading Down 0.6 %

Shares of IQV stock traded down $1.10 during trading hours on Tuesday, hitting $183.75. 1,649,439 shares of the company were exchanged, compared to its average volume of 1,207,304. The firm has a market cap of $32.36 billion, a PE ratio of 24.50, a PEG ratio of 1.99 and a beta of 1.48. IQVIA has a 1 year low of $179.81 and a 1 year high of $261.73. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The firm has a fifty day moving average of $198.52 and a 200 day moving average of $213.86.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Analysts expect that IQVIA will post 10.84 earnings per share for the current year.

Hedge Funds Weigh In On IQVIA

Several large investors have recently added to or reduced their stakes in IQV. Norges Bank bought a new position in IQVIA during the fourth quarter worth $336,041,000. Raymond James Financial Inc. bought a new position in IQVIA during the fourth quarter worth $236,120,000. American Century Companies Inc. lifted its stake in IQVIA by 396.0% during the fourth quarter. American Century Companies Inc. now owns 1,134,737 shares of the medical research company’s stock worth $222,987,000 after purchasing an additional 905,960 shares during the last quarter. Invesco Ltd. lifted its stake in IQVIA by 53.4% during the fourth quarter. Invesco Ltd. now owns 2,590,260 shares of the medical research company’s stock worth $509,012,000 after purchasing an additional 902,226 shares during the last quarter. Finally, FMR LLC lifted its stake in IQVIA by 38.7% during the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after purchasing an additional 804,963 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.